A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
Latest Information Update: 29 Apr 2025
At a glance
- Drugs FB-102 (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Therapeutic Use
- Sponsors Forte Biosciences
Most Recent Events
- 24 Apr 2025 Status changed from not yet recruiting to recruiting.
- 24 Apr 2025 Status changed from planning to not yet recruiting.
- 03 Apr 2025 New trial record